A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome

NCT ID: NCT03651726

Last Updated: 2018-08-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-31
• Study Completion Date: 2019-11-30

Brief Summary

This study evaluates the efficacy and safety of THX-110 in the management of tics and other symptoms (e.g. rage attacks, anxiety, depression, sleep difficulties) in patients with Tourette syndrome. In the first part of the study, half of the patients will receive THX-110, while the other half will receive a placebo. After completion of the first study part, patients will have the opportunity to continue into the second part of the study. In this part, all participants will receive THX-110.

Detailed Description

THX-110 is an investigational drug and is being developed for the treatment of patients with Tourette syndrome and other conditions. THX-110 consists of an active substance from cannabis (dronabinol, tetrahydrocannabinol, THC) and PEA, a substance that occurs naturally in the human body, in animals and plants.

Dronabinol and similar active substances are already approved in some countries for the treatment of other conditions. In some countries, various cannabis-based medications are currently being used in the treatment of patients with Tourette syndrome, mostly without official approval.

PEA has already been used and well tolerated in numerous clinical trials. The combination of PEA and dronabinol is assumed to show better efficacy compared to treatment with dronabinol alone.

The planned study will evaluate the efficacy of THX-110 in the management of tics and other symptoms in patients with Tourette syndrome. Other objectives are to assess study drug dosage and to identify side effects that may be associated with the study drug.

In the first part of the study, half of the patients will receive THX-110, while the other half will receive a placebo. The treatment phase will last 12 weeks. After completion of the first part, patients can decide if they want to participate in the second part of the study. In this optional second part of the study, all patients will receive THX-110 for 12 weeks.

Conditions

Tourette Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

THX-110 (dronabinol plus PEA)

Double-blind phase and extension open label phase:

Dose range of 2.5 mg to 10 mg dronabinol (1 to 4 capsules) plus 800 mg PEA (2 tablets) taken orally once daily; starting dose is 2.5 mg dronabinol plus 800 mg PEA. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose.

Group Type: EXPERIMENTAL

THX-110 (dronabinol plus PEA)

Intervention Type: DRUG

2.5 mg dronabinol capsules and 400 mg PEA tablets

Placebo

Double-blind phase:

Range of 1 to 4 dronabinol placebo capsules plus 2 PEA placebo tablets taken orally once daily; starting dose is 1 dronabinol placebo capsule plus 2 PEA placebo tablets. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets

Interventions

THX-110 (dronabinol plus PEA)

2.5 mg dronabinol capsules and 400 mg PEA tablets

Intervention Type: DRUG

Placebo

Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets

Intervention Type: DRUG

Other Intervention Names

Dronabinol; Tetrahydrocannabinol; THC; Palmidrol; Palmitoylethanolamide

Eligibility Criteria

Inclusion Criteria

1. Tourette syndrome according to DSM-5

2. Male and female subjects with an age between ≥18 and <65 years

3. Total tic score (TTS) of the YGTSS >18

4. CGI-S ≥4

5. Medication (and stimulation parameters for deep brain stimulation) for tics and comorbidities must be on a stable dose for at least 6 weeks before entering the study and subject must consent to maintain the stable dose during the study

6. Signed written informed consent and willingness to comply with treatment and follow-up procedures

7. Subjects capable of understanding the investigational nature, potential risks and benefits of the clinical study

8. Women of child-bearing potential must have a negative pregnancy test (i.e., negative for urine human chorionic gonadotropin [hCG]) before first treatment with study medication. They must practice a highly effective, reliable and medically approved contraceptive regimen during the study (e.g., theoretical failure rate less than 1% per year a when used consistently and correctly), which include oral or parenteral or implanted hormonal contraception, vaginal ring releasing hormonal contraception (e.g., Nuvaring), intrauterine device or intrauterine system. Post-menopausal women may enter this study. Post-menopausal women are defined as those without menses in the past 12 months without an alternative medical cause, and with a serum follicle stimulating hormone (FSH) in the post-menopausal range. Women who are surgically sterile may enter this study with historical documentation of surgical procedure (bilateral tubal ligation or bilateral oophorectomy at least 6 weeks prior screening or hysterectomy or uterine agenesis) and a negative pregnancy test.

9. Male subjects must be willing to use a condom with sexual partners during this study and for a period of three months following the last administration of study medication until the follow-up visit. Male subjects must be willing to abstain from sperm donation for 3 months after the completion of this study.

Exclusion Criteria

1. Comorbid OCD, ADHD, depression, or anxiety disorder when unstable and/or in need of an initial adjustment for a therapy

2. Presence of a comorbid psychiatric condition as developmental disability, psychotic illness or bipolar disorder

3. Ongoing behavioural treatment for tics

4. History of schizophrenia, seizure, psychotic, severe personality, or pervasive developmental disorder

5. Current clinical diagnosis of substance abuse or dependence

6. History of cannabis dependence

7. Secondary and other chronic tic disorders or other significant neurological disorders

8. History of severe cardiac diseases, severe cardiovascular diseases, severe renal disorders, or severe hepatic diseases and/or positive for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B

9. Concomitant medications have to be on stable dose since at least 6 weeks before entering the study and must be well tolerated at baseline without causing dizziness, confusion, sedation, or somnolence such as central nervous system depressants (e.g., barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, muscle relaxants)

10. Use of cannabis or CBM in the 30-day period prior to study entry and/or positive delta-9-THC urine test at baseline

11. Positive pregnancy test, i.e., positive for urine beta-hCG

12. Pregnant or breast-feeding women

13. Subjects who received any investigational medication or used any investigational device within 30 days prior to the first dose of study medication or is actively participating in any investigational drug or device study, or is scheduled to receive an investigational drug or to use an investigational device during the course of the study

14. Subjects with a known allergy, hypersensitivity, or intolerance to the active substances and/or excipients of study medication (e.g., cannabis, cannabinoids, sesame oil)

15. Any condition, which in the opinion of the investigator, would interfere with the evaluation of the study product or poses a health risk to the subject

16. Subjects who are employees of the sponsor or employees or close relatives of the investigator

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

FGK Clinical Research GmbH

INDUSTRY

Sponsor Role: collaborator

SciSparc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kirsten Müller-Vahl, Prof. Dr.

Role: STUDY_CHAIR

Medizinische Hochschule Hannover, Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie

Locations

Medizinische Hochschule Hannover, Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie

Hanover, , Germany

LMU Klinikum der Universität München, Klinik für Psychiatrie und Psychotherapie

Munich, , Germany

Countries

Germany

Central Contacts

Kirsten Müller-Vahl, Prof. Dr.

Role: CONTACT

mueller-vahl.kirsten@mh-hannover.de

+49 511 532 ext. 551

Christoph Schindler, Prof. Dr.

Role: CONTACT

schindler.christoph@mh-hannover.de

+49 511 5350 ext. 8300

Facility Contacts

Kirsten Müller-Vahl, Prof. Dr.

Role: primary

Richard Musil, Dr. med.

Role: primary

Other Identifiers

THX-G18-001

Identifier Type: -

Identifier Source: org_study_id